(CercleFinance.com) – Novavax announced today that the Standing Committee on Vaccination (STIKO) in Germany has expanded its recommendations for the use of Nuvaxovid as a booster for COVID-19.
STIKO recommends Nuvaxovid as a booster in adults aged 18 and older who have specific medical contraindications to COVID-19 mRNA vaccines or who request Nuvaxovid after appropriate consultation.
STIKO specifies that Nuvaxovid should be administered at intervals of at least six months after a previous immunological event (infection or vaccination).
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
